Smart dosing: antibiotic tailored to each senior patient
NCT ID NCT07127185
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aims to improve how the antibiotic ceftobiprole is dosed in patients aged 60 and older. Because older adults process drugs differently, standard doses can be too weak or too strong. Researchers will measure drug levels in blood and urine, then use computer models to adjust each patient's dose for best effect. The goal is to create a personalized dosing system that reduces risks and improves treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceftobiprole (an antibiotic)
What this could lead to
If successful, this could lead to safer, more effective antibiotic dosing tailored to elderly patients, reducing side effects and treatment failures.
What could go wrong
This is an early-stage observational study (not yet recruiting) with only 150 participants. It focuses on building a dosing model, not on proving clinical outcomes, so direct patient benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEFTOBIPROLE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••